October 18, 2016 / 12:42 PM / 9 months ago

BRIEF-Insmed inc announces publication of phase 2 study of Arikayce

1 Min Read

Oct 18 (Reuters) - Insmed Inc :

* Insmed inc - insmed announces publication of phase 2 study of arikayce in treatment-refractory nontuberculous mycobacterial lung disease

* Insmed inc - primary endpoint in study was not reached

* Insmed - data from study suggest addition of arikayce to guideline-based multi-drug regimen can achieve early and sustained negative sputum cultures

* Insmed - phase 3 study is enrolling adult non-cystic fibrosis patients with an ntm lung infection caused by mycobacterium avium complex Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below